1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Cancer	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	one	_	_	CD	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	important	_	_	JJ	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	deadly	_	_	JJ	_	_	_	_	_
10	diseases	_	_	NNS	_	_	_	_	_
11	worldwide	_	_	RB	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Reports	_	_	NNS	_	_	_	_	_
2	from	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	World	_	_	NNP	_	_	_	_	_
5	Health	_	_	NNP	_	_	_	_	_
6	Organization	_	_	NNP	_	_	_	_	_
7	show	_	_	VBP	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	almost	_	_	RB	_	_	_	_	_
10	1	_	_	CD	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	6	_	_	CD	_	_	_	_	_
13	deaths	_	_	NNS	_	_	_	_	_
14	worldwide	_	_	RB	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	2018	_	_	CD	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	due	_	_	JJ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	cancer	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Chemotherapy	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	common	_	_	JJ	_	_	_	_	_
5	approach	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	cancer	_	_	NN	_	_	_	_	_
8	treatment	_	_	NN	_	_	_	_	_
9	;	_	_	:	_	_	_	_	_
10	it	_	_	PRP	_	_	_	_	_
11	uses	_	_	VBZ	_	_	_	_	_
12	drugs	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	kill	_	_	VB	_	_	_	_	_
15	cancer	_	_	NN	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	various	_	_	JJ	_	_	_	_	_
4	limitations	_	_	NNS	_	_	_	_	_
5	affect	_	_	VBP	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	efficiency	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	chemotherapy	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	most	_	_	JJS	_	_	_	_	_
5	chemotherapeutics	_	_	NNS	_	_	_	_	_
6	possess	_	_	VBP	_	_	_	_	_
7	poor	_	_	JJ	_	_	_	_	_
8	aqueous	_	_	JJ	_	_	_	_	_
9	solubility	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	harm	_	_	VB	_	_	_	_	_
12	normal	_	_	JJ	_	_	_	_	_
13	cell	_	_	NN	_	_	_	_	_
14	toxicity	_	_	NN	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	lack	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	selectivity	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	cause	_	_	VB	_	_	_	_	_
24	multidrug	_	_	NN	_	_	_	_	_
25	resistance	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	handle	_	_	VB	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	shortcomings	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	researchers	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	proposed	_	_	VBN	_	_	_	_	_
9	nano-particles	_	_	NNS	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	novel	_	_	JJ	_	_	_	_	_
12	drug	_	_	NN	_	_	_	_	_
13	carriers	_	_	NNS	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	help	_	_	VB	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	cope	_	_	VB	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	cancer	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Nanoparticles	_	_	NNS	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	like	_	_	IN	_	_	_	_	_
4	vesicles	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	nanotubes	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	micelles	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	nanofibers	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	nanosheet	_	_	NN	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	typically	_	_	RB	_	_	_	_	_
16	commonly	_	_	RB	_	_	_	_	_
17	formed	_	_	VBN	_	_	_	_	_
18	by	_	_	IN	_	_	_	_	_
19	amphiphilic	_	_	JJ	_	_	_	_	_
20	copolymers	_	_	NNS	_	_	_	_	_
21	via	_	_	IN	_	_	_	_	_
22	self-assembly	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Nanoparticles	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	encapsulate	_	_	VB	_	_	_	_	_
4	drugs	_	_	NNS	_	_	_	_	_
5	via	_	_	IN	_	_	_	_	_
6	physical	_	_	JJ	_	_	_	_	_
7	entrapment	_	_	NN	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	solubilization	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	achieve	_	_	VB	_	_	_	_	_
12	various	_	_	JJ	_	_	_	_	_
13	advantages	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	including	_	_	VBG	_	_	_	_	_
16	controlled	_	_	VBN	_	_	_	_	_
17	drug	_	_	NN	_	_	_	_	_
18	release	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	decreased	_	_	VBN	_	_	_	_	_
21	cytotoxicity	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	increased	_	_	VBN	_	_	_	_	_
24	aqueous	_	_	JJ	_	_	_	_	_
25	solubility	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	targeted	_	_	VBN	_	_	_	_	_
29	action	_	_	NN	_	_	_	_	_
30	site	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	nanoparticles	_	_	NNS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	opened	_	_	VBN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	door	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	developing	_	_	VBG	_	_	_	_	_
10	effective	_	_	JJ	_	_	_	_	_
11	drug	_	_	NN	_	_	_	_	_
12	delivery	_	_	NN	_	_	_	_	_
13	schemes	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	have	_	_	VBP	_	_	_	_	_
16	shown	_	_	VBN	_	_	_	_	_
17	substantial	_	_	JJ	_	_	_	_	_
18	potential	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	applications	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	life-threatening	_	_	JJ	_	_	_	_	_
23	disease	_	_	NN	_	_	_	_	_
24	treatments	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	such	_	_	JJ	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	cancer	_	_	NN	_	_	_	_	_
29	therapy	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Chemotherapy	_	_	NN	_	_	_	_	_
2	usually	_	_	RB	_	_	_	_	_
3	causes	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	decline	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	immunity	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	causing	_	_	VBG	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	patients	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	suffer	_	_	VB	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	bacterial	_	_	JJ	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	threatening	_	_	VBG	_	_	_	_	_
19	their	_	_	PRP$	_	_	_	_	_
20	lives	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	avoiding	_	_	VBG	_	_	_	_	_
4	bacterial	_	_	JJ	_	_	_	_	_
5	infection	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	essential	_	_	JJ	_	_	_	_	_
8	during	_	_	IN	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	therapy	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	kind	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	novel	_	_	NN	_	_	_	_	_
6	antibacterial	_	_	JJ	_	_	_	_	_
7	agent	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	antimicrobial	_	_	JJ	_	_	_	_	_
10	peptides	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	AMPs	_	_	NNS	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	have	_	_	VBP	_	_	_	_	_
15	gained	_	_	VBN	_	_	_	_	_
16	increasing	_	_	VBG	_	_	_	_	_
17	attention	_	_	NN	_	_	_	_	_
18	over	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	past	_	_	JJ	_	_	_	_	_
21	few	_	_	JJ	_	_	_	_	_
22	decades	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	AMPs	_	_	NNS	_	_	_	_	_
2	exhibit	_	_	VBP	_	_	_	_	_
3	excellent	_	_	JJ	_	_	_	_	_
4	antibacterial	_	_	JJ	_	_	_	_	_
5	capability	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	unique	_	_	JJ	_	_	_	_	_
9	antibacterial	_	_	JJ	_	_	_	_	_
10	mechanism	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	AMPs	_	_	NNS	_	_	_	_	_
2	achieve	_	_	VBP	_	_	_	_	_
3	their	_	_	PRP$	_	_	_	_	_
4	bactericidal	_	_	JJ	_	_	_	_	_
5	effect	_	_	NN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	physical	_	_	JJ	_	_	_	_	_
8	disruption	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	bacterial	_	_	JJ	_	_	_	_	_
11	membranes	_	_	NNS	_	_	_	_	_
12	;	_	_	:	_	_	_	_	_
13	however	_	_	RB	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	inducing	_	_	VBG	_	_	_	_	_
16	bacterial	_	_	JJ	_	_	_	_	_
17	drug	_	_	NN	_	_	_	_	_
18	resistance	_	_	NN	_	_	_	_	_
19	presents	_	_	VBZ	_	_	_	_	_
20	difficulty	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Research	_	_	NN	_	_	_	_	_
2	illustrates	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	such	_	_	PDT	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	unique	_	_	JJ	_	_	_	_	_
7	antibacterial	_	_	JJ	_	_	_	_	_
8	mechanism	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	relevant	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	specific	_	_	JJ	_	_	_	_	_
13	AMP	_	_	NN	_	_	_	_	_
14	structures	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	including	_	_	VBG	_	_	_	_	_
17	cationic	_	_	JJ	_	_	_	_	_
18	moieties	_	_	NNS	_	_	_	_	_
19	such	_	_	JJ	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	lysine	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	hydrophobic	_	_	JJ	_	_	_	_	_
24	moieties	_	_	NNS	_	_	_	_	_
25	such	_	_	JJ	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	phenylalanine	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Lots	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	AMPs	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	amphiphilic	_	_	JJ	_	_	_	_	_
6	peptides	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	namely	_	_	RB	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	they	_	_	PRP	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	composed	_	_	VBN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	hydrophobic	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	hydrophilic	_	_	JJ	_	_	_	_	_
17	residues	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	AMP-nanoparticles	_	_	NNS	_	_	_	_	_
2	can	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	prepared	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	aqueous	_	_	JJ	_	_	_	_	_
8	solution	_	_	NN	_	_	_	_	_
9	through	_	_	IN	_	_	_	_	_
10	self-assembly	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	these	_	_	DT	_	_	_	_	_
13	AMPs	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	AMP	_	_	NN	_	_	_	_	_
2	assemblies	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	ideal	_	_	JJ	_	_	_	_	_
5	drug	_	_	NN	_	_	_	_	_
6	delivery	_	_	NN	_	_	_	_	_
7	systems	_	_	NNS	_	_	_	_	_
8	exhibiting	_	_	VBG	_	_	_	_	_
9	both	_	_	CC	_	_	_	_	_
10	drug	_	_	NN	_	_	_	_	_
11	release	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	antibacterial	_	_	JJ	_	_	_	_	_
14	capabilities	_	_	NNS	_	_	_	_	_
15	during	_	_	IN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	group	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	reported	_	_	VBN	_	_	_	_	_
5	several	_	_	JJ	_	_	_	_	_
6	amphiphilic	_	_	JJ	_	_	_	_	_
7	block	_	_	NN	_	_	_	_	_
8	AMPs	_	_	NNS	_	_	_	_	_
9	containing	_	_	VBG	_	_	_	_	_
10	lysine	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	phenylalanine	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	AMPs	_	_	NNS	_	_	_	_	_
3	exhibit	_	_	VBP	_	_	_	_	_
4	high	_	_	JJ	_	_	_	_	_
5	bactericidal	_	_	JJ	_	_	_	_	_
6	efficiency	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	low	_	_	JJ	_	_	_	_	_
9	cytotoxicity	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Vesicles	_	_	NNS	_	_	_	_	_
2	formed	_	_	VBN	_	_	_	_	_
3	by	_	_	IN	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	AMPs	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	good	_	_	JJ	_	_	_	_	_
8	performance	_	_	NN	_	_	_	_	_
9	when	_	_	WRB	_	_	_	_	_
10	carrying	_	_	VBG	_	_	_	_	_
11	drugs	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Motivated	_	_	VBN	_	_	_	_	_
2	by	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	excellent	_	_	JJ	_	_	_	_	_
5	properties	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	promising	_	_	JJ	_	_	_	_	_
8	applications	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	AMP	_	_	NN	_	_	_	_	_
11	nanoparticles	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	synthetic	_	_	JJ	_	_	_	_	_
14	amphiphilic	_	_	JJ	_	_	_	_	_
15	AMP	_	_	NN	_	_	_	_	_
16	–	_	_	:	_	_	_	_	_
17	mimetic	_	_	JJ	_	_	_	_	_
18	polymers	_	_	NNS	_	_	_	_	_
19	are	_	_	VBP	_	_	_	_	_
20	proposed	_	_	VBN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	amphiphilic	_	_	JJ	_	_	_	_	_
3	copolymers	_	_	NNS	_	_	_	_	_
4	stimulate	_	_	VBP	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	structural	_	_	JJ	_	_	_	_	_
7	features	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	AMPs	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	cationic	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	hydrophobic	_	_	JJ	_	_	_	_	_
17	moieties	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Amphiphilic	_	_	JJ	_	_	_	_	_
2	copolymers	_	_	NNS	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	only	_	_	RB	_	_	_	_	_
5	possess	_	_	VBP	_	_	_	_	_
6	good	_	_	JJ	_	_	_	_	_
7	properties	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	such	_	_	JJ	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	unique	_	_	JJ	_	_	_	_	_
13	bactericidal	_	_	JJ	_	_	_	_	_
14	mechanism	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	capability	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	self-assembly	_	_	NN	_	_	_	_	_
20	into	_	_	IN	_	_	_	_	_
21	nanoparticles	_	_	NNS	_	_	_	_	_
22	that	_	_	WDT	_	_	_	_	_
23	are	_	_	VBP	_	_	_	_	_
24	similar	_	_	JJ	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	those	_	_	DT	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	natural	_	_	JJ	_	_	_	_	_
29	AMPs	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	but	_	_	CC	_	_	_	_	_
32	also	_	_	RB	_	_	_	_	_
33	show	_	_	VBP	_	_	_	_	_
34	more	_	_	RBR	_	_	_	_	_
35	convenient	_	_	JJ	_	_	_	_	_
36	synthesis	_	_	NN	_	_	_	_	_
37	strategy	_	_	NN	_	_	_	_	_
38	than	_	_	IN	_	_	_	_	_
39	natural	_	_	JJ	_	_	_	_	_
40	AMPs	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	work	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Zhou	_	_	NNP	_	_	_	_	_
6	et	_	_	FW	_	_	_	_	_
7	al.	_	_	FW	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	reported	_	_	VBN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	minimal	_	_	JJ	_	_	_	_	_
12	inhibition	_	_	NN	_	_	_	_	_
13	concentration	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	MIC	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	amphiphilic	_	_	JJ	_	_	_	_	_
19	copolymers	_	_	NNS	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	less	_	_	JJR	_	_	_	_	_
22	than	_	_	IN	_	_	_	_	_
23	32	_	_	CD	_	_	_	_	_
24	μg/mL	_	_	NNS	_	_	_	_	_
25	against	_	_	IN	_	_	_	_	_
26	both	_	_	CC	_	_	_	_	_
27	Gram-negative	_	_	JJ	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	Gram-positive	_	_	JJ	_	_	_	_	_
30	bacteria	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	broad	_	_	JJ	_	_	_	_	_
3	antibacterial	_	_	JJ	_	_	_	_	_
4	capability	_	_	NN	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	proved	_	_	VBN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	will	_	_	MD	_	_	_	_	_
11	play	_	_	VB	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	vital	_	_	JJ	_	_	_	_	_
14	role	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	cancer	_	_	NN	_	_	_	_	_
17	therapy	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	previous	_	_	JJ	_	_	_	_	_
4	work	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	series	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	amphiphilic	_	_	JJ	_	_	_	_	_
10	mimicked	_	_	VBN	_	_	_	_	_
11	AMP	_	_	NN	_	_	_	_	_
12	copolymers	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	PCL16-	_	_	NNP	_	_	_	_	_
15	b	_	_	NN	_	_	_	_	_
16	-Kn	_	_	FW	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	can	_	_	MD	_	_	_	_	_
20	inhibit	_	_	VB	_	_	_	_	_
21	both	_	_	CC	_	_	_	_	_
22	Gram-negative	_	_	JJ	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	Gram-positive	_	_	JJ	_	_	_	_	_
25	bacteria	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	work	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	studied	_	_	VBD	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	self-assembling	_	_	JJ	_	_	_	_	_
10	behavior	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	these	_	_	DT	_	_	_	_	_
13	block	_	_	NN	_	_	_	_	_
14	copolymers	_	_	NNS	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	aqueous	_	_	JJ	_	_	_	_	_
17	solutions	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	morphologies	_	_	NNS	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	sizes	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	nanoparticles	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	characterized	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	transmission	_	_	NN	_	_	_	_	_
11	electron	_	_	NN	_	_	_	_	_
12	microscopy	_	_	NN	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	TEM	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	dynamic	_	_	JJ	_	_	_	_	_
18	light	_	_	NN	_	_	_	_	_
19	scattering	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	DLS	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	respectively	_	_	RB	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Critical	_	_	JJ	_	_	_	_	_
2	vesiculation	_	_	NN	_	_	_	_	_
3	concentrations	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	CVCs	_	_	NNS	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	studied	_	_	VBN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Drug	_	_	NN	_	_	_	_	_
2	delivery	_	_	NN	_	_	_	_	_
3	potential	_	_	NN	_	_	_	_	_
4	was	_	_	VBD	_	_	_	_	_
5	investigated	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	in	_	_	FW	_	_	_	_	_
8	vitro	_	_	FW	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	intracellular	_	_	JJ	_	_	_	_	_
11	doxorubicin	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	DOX)-release	_	_	NN	_	_	_	_	_
14	experiments	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Based	_	_	VBN	_	_	_	_	_
2	on	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	results	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	amphiphilic	_	_	JJ	_	_	_	_	_
7	diblock	_	_	NN	_	_	_	_	_
8	copolymers	_	_	NNS	_	_	_	_	_
9	PCL16-	_	_	FW	_	_	_	_	_
10	b	_	_	NN	_	_	_	_	_
11	-Kn	_	_	NN	_	_	_	_	_
12	could	_	_	MD	_	_	_	_	_
13	serve	_	_	VB	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	efficient	_	_	JJ	_	_	_	_	_
16	drug	_	_	NN	_	_	_	_	_
17	carriers	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	cancer	_	_	NN	_	_	_	_	_
20	treatment	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Given	_	_	VBN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	excellent	_	_	JJ	_	_	_	_	_
4	antibacterial	_	_	JJ	_	_	_	_	_
5	properties	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	low	_	_	JJ	_	_	_	_	_
8	cytotoxicity	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	PCL16-	_	_	NNP	_	_	_	_	_
11	b	_	_	NN	_	_	_	_	_
12	-Kn	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	previous	_	_	JJ	_	_	_	_	_
15	works	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	such	_	_	JJ	_	_	_	_	_
18	diblock	_	_	NN	_	_	_	_	_
19	copolymer	_	_	NN	_	_	_	_	_
20	nanoparticles	_	_	NNS	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	ideal	_	_	JJ	_	_	_	_	_
24	“	_	_	``	_	_	_	_	_
25	armed	_	_	JJ	_	_	_	_	_
26	”	_	_	''	_	_	_	_	_
27	drug	_	_	NN	_	_	_	_	_
28	delivery	_	_	NN	_	_	_	_	_
29	systems	_	_	NNS	_	_	_	_	_
30	for	_	_	IN	_	_	_	_	_
31	applications	_	_	NNS	_	_	_	_	_
32	in	_	_	IN	_	_	_	_	_
33	nanomedical	_	_	JJ	_	_	_	_	_
34	fields	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_

